Journal:Acta Cryst D:S2059798322007082
From Proteopedia
(Difference between revisions)

(58 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | <StructureSection load='' size='450' side='right' scene=' | + | <StructureSection load='' size='450' side='right' scene='91/917471/Cv/2' caption=''> |
===Native glycosylation and binding of the anti-depressant paroxetine in a low-resolution crystal structure of human myeloperoxidase=== | ===Native glycosylation and binding of the anti-depressant paroxetine in a low-resolution crystal structure of human myeloperoxidase=== | ||
- | <big> | + | <big>Lucas Krawczyk, Shubham Semwal, Jalal Soubhye, Salma Lemri Ouadriri, Martine Prévost, Pierre Van Antwerpen, Goedele Roos, & Julie Bouckaert</big> <ref>doi: 10.1107/S2059798322007082</ref> |
<hr/> | <hr/> | ||
<b>Molecular Tour</b><br> | <b>Molecular Tour</b><br> | ||
+ | The human enzyme myeloperoxidase (MPO in short) is a heme-dependent peroxidase. The peroxidases are a large group of enzymes playing roles in various biological processes. MPO is found in mammalian neutrophils, which is a type of with blood cells, and there it catalyzes the oxidation of halide ions and thiocyanate in the presence of hydrogen peroxide. This results in strong oxidizing agents and they are helping to eliminate the bacteria or viruses which were taken up by phagocytosis. So, MPO is a key protein in the human immune defense system. | ||
+ | |||
+ | In order for MPO to function correctly, sugar molecules need to be present on its protein surface. This is called the glycosylation pattern. Until now, only a part of the glycosylation of MPO could be seen from the crystal structures deposited in the Protein Data Bank, holding the collection of available structures of biomolecules. Human MPO has five glycosylation sites, identified at positions Asn323, Asn355, Asn391, Asn483 and Asn729. We present here a structure in which the glycan structures on these five glycosylation sites could be identified ([[7oih]]). <scene name='91/917471/Cv/26'>The final model contains 8 polypeptide chains of mature MPO</scene> and 30 glycan chains on the Asn-binding sites. Each chain has a different colour. The 8 monomers forming <scene name='91/917471/Cv/27'>4 biological assemblies as homodimers AB, CD, EF and GH</scene> (each dimer has a different colour) in the crystal structure of human MPO, with their glycosylation structures as determined. <scene name='91/917471/Cv/28'>Monomers A, D, F and H have a bound paroxetine inhibitor</scene> (wheat), and each catalytic site carries an iron-containing <scene name='91/917471/Cv/29'>heme group</scene> (sea-green) and has an <scene name='91/917471/Cv/30'>S-hydroxy L-cysteine</scene> (CSO; in yellow) within 12 Å distance from the heme group. All <scene name='91/917471/Cv1/7'>N-glycosylation</scene> starts with an N-acetylglucosamine (white), modifying the labelled asparagine, and many are further substituted also with mannose (pale green) and fucose (violet). Possible positions Asn323, Asn355, Asn391, Asn483 and Asn729 are labelled. Changes are possible due to N-glycan remodeling that occur post biogenesis and each glycosylation site may hold a truly individual protein function. For example, only the Asn323 site carries the peculiar phosphomannosylation, that it may be use to traffic into azurophilic granules. We compare these with the glycans identified in proteomics studies and from eighteen human MPO structures available in the PDB. | ||
+ | |||
+ | <scene name='91/917471/Cv/31'>Glycosylation of both monomer chains G (blue) and H (gold) of one MPO homodimer</scene>. Two N-glycans pack tightly with each other at the dimer interface. The heme groups are present in both monomers and are shown as a sea green spacefill model. Paroxetine (spacefill model) is bound in one monomer per dimer (chain H). Green spheres represent chloride ions, pink spheres are calcium ions and CPK compositions are phosphate ions. <scene name='91/917471/Cv2/14'>Interactions between N-glycans with each other and protein at the dimer interface</scene>. Inter- and intermolecular hydrogen bonds, inclusive with water molecules (shown as red spheres), are shown as white dashed lines. <scene name='91/917471/Cv2/15'>Stacking of the N-glycans FA1[6] on Asn483 of MPO monomer chains G and H of one MPO homodimer</scene>, by symmetrically using N-acetylglucosamine (white, middle) β1,2-linked to the α1,6 arm of the trimannose core (pale green) and the fucose (violet) α1,6-linked to the core GlcNAc1. | ||
+ | |||
+ | <scene name='91/917471/Cv2/16'>The MPO catalytic site</scene> carries an iron-containing heme group. The heme group of MPO and the near binding of the thiocyanate, a natural substrate, and paroxetine, an inhibitor, as found in the monomer with chain A are shown. Amino acid numbering is based on the pro-MPO crystal structure numbering, including signal and pro-peptide. Our structure also contains <scene name='91/917471/Cv2/17'>bound paroxetine</scene>, a recently discovered inhibitor of MPO, previously used as anti-depressant. The bound paroxetine was always found in the presence of <scene name='91/917471/Cv2/18'>thiocyanate</scene>, a physiological substrate of MPO. A lot of effort has been undertaken into inhibitor design, as things can also go wrong with MPO. When things go wrong, MPO is released into the extracellular fluid. This circulating MPO damages host tissue as the reaction products of MPO can oxidize biomolecules (lipids, DNA and proteins). So, MPO is involved in a lot of pathologies, either as a source or to make the symptoms worse of existing pathologies, creating a large interest into the design of molecules in order to block this circulating MPO. | ||
+ | |||
+ | <scene name='91/917471/Cv2/13'>Superposition</scene> of PDB entry [[1dnu]] (blue) containing thiocyanate (SCN-) with chain A of the MPO crystal structure (wheat), bound to SCN- and paroxetine. | ||
+ | <jmol><jmolButton><script>frame 1 1 play; animation off; frame 1</script><text>only present MPO structure</text></jmolButton><jmolButton><script>frame 2 2 play; animation off; frame 2</script><text>only 1dnu</text></jmolButton><jmolButton><script>animation off; frame all</script><text>both present MPO structure and 1dnu</text></jmolButton></jmol> | ||
<b>References</b><br> | <b>References</b><br> |
Current revision
|
This page complements a publication in scientific journals and is one of the Proteopedia's Interactive 3D Complement pages. For aditional details please see I3DC.